Piperacillin/tazobactam has demonstrated excellent potency test results of 23 generic lots reported in 2008-2009. In the comparisons of eight branded lots to the RLOT, the branded lots had greater activity correlations (-6%) compared to the generic potency. Generic product use should consider acceptable -10% lower limit (Table 1 and Figure 1). Only 3 of 46 generic lots were within 10% of control potency. The objective of this expanded study was three-fold: 1) to assess the reproducibility of the assay method via replicate tests over 22 months was determined. The latter exercise compared to -35% (average, -16%; see Figure 1). This demonstrates a sustained high level of activity (83% acceptable) and a slight decrease in susceptibility (average, only -6%) and the reproducibility (13 replicates) of the RLOT was -19% (average, -6%)

**RESULTS**

Piperacillin/tazobactam has become a very widely used intravenous penicillin-beta-lactamase inhibitor combination delivered as an 8:1 ratio of piperacillin and 0.5 gram of tazobactam in several global markets, but have been questioned as to their potency when compared to the product. Problems with generic formulations related to excessive imputities and suboptimal activity performance in earlier testing (ECCMID, Eurofarma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Europharma, 121609C) only varied from 0 to -35% (average, -16%; consistent with RLOT reproducibility of some lots (Eu...